MarketCap
Repligen Corporation RGEN
$ 180.01
2.42%
Facebook
X
Telegram
Repligen Corporation General and Administrative Expenses | RGEN
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Repligen Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 291 M | 263 M | 219 M | 216 M | 184 M | 120 M | 95.6 M | 65.7 M | 51.5 M | 30.9 M | 24.7 M | 17.2 M | 12.7 M | 13.2 M | 8.02 M | 5.58 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 291 M | 5.58 M | 101 M |
Quarterly General and Administrative Expenses Repligen Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 76.6 M | 76.5 M | 73.7 M | 71.2 M | 71.3 M | - | 75.6 M | 65.5 M | 61.8 M | - | 55.6 M | 49 M | 56.2 M | - | 53.6 M | 54.6 M | 54.3 M | - | 48.4 M | 44.3 M | 39.1 M | - | 29.1 M | 26.7 M | 27.5 M | - | 24.6 M | 23.7 M | 19 M | - | 15.9 M | 16.6 M | 15.9 M | 16.1 M | 15 M | 11.2 M | 9.18 M | 8.57 M | 7.13 M | 8.14 M | 7.02 M | 6.47 M | 5.96 M | 6.24 M | 6.02 M | 4.98 M | 4.47 M | 4.33 M | 3.38 M | 3.37 M | 2.9 M | 3.12 M | 3.31 M | 3.25 M | 3.13 M | 3.42 M | 3.43 M | 4.27 M | 2.49 M | 2.29 M | 2.44 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 76.6 M | 2.29 M | 25.7 M |
General and Administrative Expenses of other stocks in the Medical instruments industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioLife Solutions
BLFS
|
45.5 M | $ 38.61 | 3.51 % | $ 1.84 B |  USA |
 |
Harvard Bioscience
HBIO
|
17.7 M | $ 8.32 | 1.09 % | $ 369 M | USA |
 |
ICU Medical
ICUI
|
625 M | $ 165.91 | -0.46 % | $ 4.09 B | USA |
 |
InfuSystem Holdings
INFU
|
57 M | $ 13.8 | -1.0 % | $ 285 M | USA |
 |
iRhythm Technologies
IRTC
|
493 M | $ 121.86 | 0.49 % | $ 3.9 B | USA |
 |
Intuitive Surgical
ISRG
|
2.38 B | $ 451.72 | -0.13 % | $ 161 B | USA |
 |
LeMaitre Vascular
LMAT
|
42 M | $ 84.26 | -0.22 % | $ 1.91 B | USA |
 |
Nephros
NEPH
|
9 M | $ 3.6 | 1.98 % | $ 38.2 M | USA |
 |
Envista Holdings Corporation
NVST
|
1.16 B | $ 23.68 | 0.32 % | $ 3.98 B | USA |
 |
OraSure Technologies
OSUR
|
47.7 M | $ 4.17 | 0.97 % | $ 306 M | USA |
 |
Pro-Dex
PDEX
|
8 M | $ 61.53 | -1.11 % | $ 198 B | USA |
 |
Pulse Biosciences
PLSE
|
32 M | $ 52.77 | -0.47 % | $ 3.56 B | USA |
 |
ResMed
RMD
|
1.12 B | $ 253.31 | 0.18 % | $ 36.9 B | USA |
 |
Retractable Technologies
RVP
|
12.8 M | $ 0.58 | -0.02 % | $ 17.4 M | USA |
 |
STAAR Surgical Company
STAA
|
85.8 M | $ 23.16 | 2.43 % | $ 1.15 B | USA |
 |
STERIS plc
STE
|
1.41 B | $ 229.89 | -0.97 % | $ 22.6 B | USA |
 |
Stereotaxis
STXS
|
17.8 M | $ 0.99 | -2.99 % | $ 90 M | USA |
 |
Teleflex Incorporated
TFX
|
720 M | $ 137.03 | 0.54 % | $ 6.11 B | USA |
 |
Utah Medical Products
UTMD
|
7.88 M | $ 73.36 | -1.17 % | $ 238 M | USA |
 |
Atrion Corporation
ATRI
|
23.2 K | - | - | $ 810 M | USA |
 |
West Pharmaceutical Services
WST
|
394 M | $ 395.17 | 0.77 % | $ 28.6 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
1.44 B | $ 9.22 | -2.28 % | $ 1.84 B | USA |
 |
NeuroMetrix
NURO
|
6.33 M | - | 5.05 % | $ 9.02 M | USA |
 |
AngioDynamics
ANGO
|
43.7 M | $ 12.17 | -1.62 % | $ 505 M | USA |
 |
Becton, Dickinson and Company
BDX
|
5.28 B | $ 195.87 | -1.37 % | $ 56.3 B | USA |
 |
The Cooper Companies
COO
|
1.63 B | $ 61.11 | -0.16 % | $ 12.2 B | USA |
 |
electroCore
ECOR
|
38.2 M | $ 7.51 | 6.52 % | $ 63.7 K | USA |
 |
Glaukos Corporation
GKOS
|
332 M | $ 178.61 | -0.15 % | $ 10.2 B | USA |
 |
Haemonetics Corporation
HAE
|
442 M | $ 119.33 | 0.69 % | $ 5.63 B | USA |
 |
Repro Med Systems
KRMD
|
23.4 M | $ 3.13 | -1.26 % | $ 145 M | USA |
 |
Milestone Scientific
MLSS
|
11.6 M | $ 0.31 | 1.02 % | $ 25.4 M | USA |
 |
Merit Medical Systems
MMSI
|
455 M | $ 94.16 | 0.92 % | $ 5.57 B | USA |
 |
Alcon
ALC
|
3.45 B | $ 70.0 | -0.24 % | $ 34.5 B |  Schweiz |
 |
CRH Medical Corporation
CRHM
|
8.44 M | - | - | $ 282 M | USA |
 |
AtriCure
ATRC
|
311 M | $ 61.13 | 3.66 % | $ 2.92 B | USA |
 |
Cantel Medical Corp.
CMD
|
198 M | - | -1.18 % | $ 3.4 B | USA |
 |
Baxter International
BAX
|
2.89 B | $ 25.28 | -0.08 % | $ 13 B | USA |
 |
Microbot Medical
MBOT
|
8.46 M | $ 0.95 | -2.44 % | $ 43.5 M |  Israel |
 |
Luminex Corporation
LMNX
|
140 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
3.73 M | - | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
62.8 M | - | - | $ 955 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
941 M | - | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
671 M | - | -0.02 % | $ 16.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
19.8 M | - | - | $ 28.6 M | USA |
 |
Isoray
ISR
|
30.2 M | - | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
744 M | - | - | $ 9.59 B | USA |
 |
Predictive Oncology
POAI
|
25.9 M | - | - | $ 31.1 M | USA |